Collaboration Strategy Launched by Altasciences and VoxCell BioInnovation to Accelerate Preclinical Pharmaceutical Research
In a recent press release issued by Business Wire, Altasciences and VoxCell BioInnovation have announced a strategic collaboration aimed at enhancing preclinical research and accelerating the path from drug discovery to clinical trials.
Based in Victoria, British Columbia, Canada, VoxCell BioInnovation is a biotechnology startup founded in 2020. The company specializes in advancing the future of in vitro modeling for oncology research and drug development. VoxCell's goal is to reduce translational gaps and accelerate biomedical innovation.
The partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's 3D tissue technology. This integration seeks to create a more predictive and human-relevant preclinical testing environment.
VoxCell's high-resolution 3D bioprinted tissues closely replicate the structure and behavior of human tumors and other biological tissues. By adopting such human-relevant models early in drug development, both companies expect to speed decision-making for their clients, reduce failures later in development, and ultimately bring better therapies to patients faster.
Initially, the focus of this partnership will be on drug screening for ocular diseases. However, plans are in place to expand into other therapeutic areas over time.
Altasciences, an integrated drug development solution company, offers services including preclinical and clinical pharmacology studies, formulation, manufacturing, and analytical services. The company has been partnering with sponsors for over 30 years to support educated, faster, and more complete early drug development decisions.
For media inquiries at Altasciences, contact Julie-Ann Cabana at [email protected]. To learn more about Altasciences, visit altasciences.com. To learn more about VoxCell, visit voxcellbio.com.
VoxCell's consumable products are used by pharmaceutical companies, biotech firms, Contract Research Organizations (CROs), and academic researchers. The goal of this collaboration is to reduce R&D timelines and increase the success rate of investigational therapies by integrating VoxCell's 3D bioprinted tissue platforms into Altasciences' services.
Both Altasciences and VoxCell emphasize their commitment to innovation, efficiency, and adherence to the 3Rs principle (Reduce, Replace, Refine animal use in research), aligning their efforts to advance smarter and more ethical science in drug development.
- The collaboration between Altasciences and VoxCell, rooted in data-and-cloud-computing technology, aims to integrate VoxCell's 3D bioprinted tissue platforms into Altasciences' services, potentially reducing R&D timelines and increasing the success rate of investigational therapies.
- In the realm of finance and business, this strategic partnership seeks to bring better therapeutics to patients faster, as they initially focus on drug screening for ocular diseases, with plans to expand into other therapeutic areas over time.
- By adopting VoxCell's high-resolution, human-relevant 3D bioprinted tissues early in drug development, both companies anticipate expediting decision-making for their clients, thereby reducing failures later in the development process and ultimately contributing to advancements in cloud-based technology in the pharmaceutical and research industries.
